Who are Placebo to DOR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DOR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-dor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo to DOR — Competitive Intelligence Brief

Placebo to DOR (Placebo to DOR) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Delta opioid receptor agonist. Area: Pain Management.

phase 3 Delta opioid receptor agonist DOR (Delta opioid receptor) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to DOR (Placebo to DOR) — Merck Sharp & Dohme LLC. DOR is a delta opioid receptor agonist that activates delta opioid receptors to modulate pain signaling and potentially provide analgesic effects.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo to DOR TARGET	Placebo to DOR	Merck Sharp & Dohme LLC	phase 3	Delta opioid receptor agonist	DOR (Delta opioid receptor)
DOR	DOR	Merck Sharp & Dohme LLC	marketed	Delta opioid receptor agonist	Delta opioid receptor (DOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Delta opioid receptor agonist class)

Merck Sharp & Dohme LLC · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to DOR — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-dor. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab